AI Is Cutting Drug Development Costs by 70% and Big Pharma Is Salivating

What the Numbers Actually Say

Axios is reporting on a TD Cowen survey of 80 biopharma leaders and insiders that finds AI is slashing preclinical costs and timelines by as much as 70%. That is not a rounding error. That is a structural shift in how experimental drugs get made, and it is happening right now, not in some speculative future.

The survey points to surging demand for specialized software, sequencing tools, and computational models that can churn out more experimental treatments over the next five years. The pipeline is about to get a lot wider. Whether that translates into more affordable medicine for actual human beings is, of course, a completely separate question that nobody in a boardroom is rushing to answer.

The Part Everyone Is Glossing Over

Here is the thing about a 70% reduction in preclinical costs: somebody has to ask where those savings are going. Drug companies have spent years telling Congress, patients, and anyone who would listen that sky-high drug prices exist because research is brutally expensive and risky. Fine. That argument had at least some structural logic behind it, even if the industry abused it relentlessly.

If AI genuinely cuts those costs by 70%, and the TD Cowen survey suggests it is already doing exactly that, then the entire justification for pricing insulin like it's hand-carved from gold starts to crumble. Watch carefully over the next few years whether those savings show up in drug prices or exclusively in shareholder returns. History suggests you should not hold your breath.

Axios notes that AI cannot replace scientific intuition. That caveat is doing a lot of heavy lifting for an industry that is clearly preparing to automate a significant chunk of its early research workforce. "AI can't replace scientific intuition" is the pharmaceutical version of "we value our employees" right before the layoffs hit.

What Is Actually Changing in the Lab

The preclinical phase of drug development is where most experimental treatments go to die. Compounds get screened, tested in cell cultures and animal models, and the vast majority wash out before a human being ever sees them. It is expensive, time-consuming, and statistically brutal. AI is changing that by processing enormous datasets, identifying promising compounds faster, and predicting which candidates are likely to fail before you burn years and millions of dollars on them.

According to the TD Cowen survey cited by Axios, that efficiency is already fueling demand for the underlying infrastructure: the sequencing tools, the proprietary models, the specialized software platforms that make this kind of analysis possible. There is a whole ecosystem of companies that have positioned themselves to sell picks and shovels to the pharma gold rush, and right now business is very good for them.

The Automation Push Nobody Is Talking About Honestly

The survey finds AI is "priming a bigger automation push" across early-stage research. That phrase is worth sitting with for a second. Biopharma is a highly educated, highly specialized workforce. The people doing preclinical research are not line workers who lack political leverage. They have PhDs. They have professional organizations. They have options.

And yet the industry is openly telling investors that it is building toward more automation, faster throughput, and leaner research operations. The TD Cowen survey is not a leaked internal memo. It is something biopharma leaders said out loud to analysts who promptly published it. The automation push is not coming. It is here, and the people who run these companies are proud of it.

The question of what happens to the humans in this equation gets buried in the enthusiasm about compressed timelines and exciting new treatments. It always does.

Five Years From Now

The survey projects that AI-driven tools will help produce significantly more experimental treatments over the next five years. More candidates in the pipeline is genuinely good news if it translates into faster cures for diseases that currently have none. There are real people with real diseases who need breakthroughs that have been agonizingly slow to arrive. Nobody should dismiss that.

But the pharmaceutical industry's track record on using structural advantages to benefit patients rather than investors is, to put it charitably, mixed. Drug companies have had patent protections, government-funded research, orphan drug designations, and favorable regulatory environments for decades. Access to affordable medicine has not exactly kept pace. AI will be the most powerful tool the industry has ever had. Whether it will be used differently than every other advantage that came before it is the only question that actually matters.